Is Sacubitril/Valsartan Antifibrotic?

[1]  S. Solomon,et al.  Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. , 2019, Journal of the American College of Cardiology.

[2]  S. Solomon,et al.  Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial , 2018, European journal of heart failure.

[3]  N. Sattar,et al.  Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure , 2018, Heart.

[4]  S. Heymans,et al.  Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis , 2017, ESC heart failure.

[5]  F. Zannad,et al.  Myocardial fibrosis: biomedical research from bench to bedside , 2017, European journal of heart failure.

[6]  M. Flather,et al.  Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study , 2017, Clinical Research in Cardiology.

[7]  G. Condorelli,et al.  Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis: Beyond Spironolactone? , 2016, Journal of the American College of Cardiology.

[8]  S. Heymans,et al.  Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential , 2015, European journal of heart failure.

[9]  Arantxa González,et al.  Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. , 2015, Journal of the American College of Cardiology.

[10]  B. Pitt,et al.  Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study , 2009, Circulation.

[11]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.